BRPI0516170A - formas de dosagens farmacêuticas estáveis e amorfas de compostos de rapamicina - Google Patents

formas de dosagens farmacêuticas estáveis e amorfas de compostos de rapamicina

Info

Publication number
BRPI0516170A
BRPI0516170A BRPI0516170-3A BRPI0516170A BRPI0516170A BR PI0516170 A BRPI0516170 A BR PI0516170A BR PI0516170 A BRPI0516170 A BR PI0516170A BR PI0516170 A BRPI0516170 A BR PI0516170A
Authority
BR
Brazil
Prior art keywords
pharmaceutical dosage
stable
dosage forms
rapamycin compounds
compounds
Prior art date
Application number
BRPI0516170-3A
Other languages
English (en)
Inventor
Cynthia A Maryanoff
Karl Pieter Stefaan Six
Roger Petrus Gerebe Vandecruys
Original Assignee
Cordis Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cordis Corp filed Critical Cordis Corp
Publication of BRPI0516170A publication Critical patent/BRPI0516170A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

FORMAS DE DOSAGENS FARMACêUTICAS ESTáVEIS E AMORFAS DE COMPOSTOS DE RAPAMICINA. A presente invenção refere-se a uma forma de dosagem farmacêutica compreendendo compostos na forma estável e amorfa do tipo rapamicina e um excipiente farmaceuticamente aceitável, além de métodos de fabricação da dita forma de dosagem farmacêutica.
BRPI0516170-3A 2004-09-29 2005-09-28 formas de dosagens farmacêuticas estáveis e amorfas de compostos de rapamicina BRPI0516170A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61413904P 2004-09-29 2004-09-29
PCT/US2005/034433 WO2006039237A1 (en) 2004-09-29 2005-09-28 Pharmaceutical dosage forms of stable amorphous rapamycin like compounds

Publications (1)

Publication Number Publication Date
BRPI0516170A true BRPI0516170A (pt) 2008-08-26

Family

ID=35466416

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0516170-3A BRPI0516170A (pt) 2004-09-29 2005-09-28 formas de dosagens farmacêuticas estáveis e amorfas de compostos de rapamicina

Country Status (11)

Country Link
US (1) US20060094744A1 (pt)
EP (1) EP1809247A1 (pt)
JP (1) JP2008514706A (pt)
KR (1) KR20070083839A (pt)
CN (1) CN101076319A (pt)
AU (1) AU2005292339A1 (pt)
BR (1) BRPI0516170A (pt)
CA (1) CA2581169A1 (pt)
IL (1) IL182255A0 (pt)
MX (1) MX2007003731A (pt)
WO (1) WO2006039237A1 (pt)

Families Citing this family (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007011708A2 (en) * 2005-07-15 2007-01-25 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
JP5756588B2 (ja) 2005-07-15 2015-07-29 ミセル テクノロジーズ、インコーポレイテッド 制御されたモルホロジーの薬剤粉末を含むポリマーコーティング
CA2650590C (en) 2006-04-26 2018-04-03 Micell Technologies, Inc. Coatings containing multiple drugs
US10695327B2 (en) 2006-09-13 2020-06-30 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
WO2008033956A2 (en) 2006-09-13 2008-03-20 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
US8088789B2 (en) 2006-09-13 2012-01-03 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
US8636767B2 (en) * 2006-10-02 2014-01-28 Micell Technologies, Inc. Surgical sutures having increased strength
CA2667228C (en) 2006-10-23 2015-07-14 Micell Technologies, Inc. Holder for electrically charging a substrate during coating
US20080138405A1 (en) * 2006-12-06 2008-06-12 Raheja Praveen Sirolimus nanodispersion
CN101711137B (zh) 2007-01-08 2014-10-22 米歇尔技术公司 具有可生物降解层的支架
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
RU2447901C2 (ru) 2007-01-21 2012-04-20 Хемотек Аг Медицинский продукт для лечения обтураций просветов организма и для предупреждения угрожающих повторных обтураций
EP1952807A1 (en) * 2007-01-24 2008-08-06 LEK Pharmaceuticals D.D. Sirolimus formulation
CA2681628C (en) 2007-03-16 2016-10-18 Concert Pharmaceuticals, Inc. Inhibitors of cholesterol ester transfer protein
US8198305B2 (en) * 2007-04-13 2012-06-12 Concert Pharmaceuticals Inc. 1,2-benzisoxazol-3-yl compounds
WO2008131131A1 (en) * 2007-04-17 2008-10-30 Micell Technologies, Inc. Stents having biodegradable layers
KR20100105802A (ko) * 2007-04-19 2010-09-29 콘서트 파마슈티컬즈, 인크. 중수소화된 모르폴리닐 화합물
ES2401914T3 (es) 2007-04-25 2013-04-25 Concert Pharmaceuticals Inc. Análogos de Cilostazol
MX341177B (es) 2007-05-01 2016-08-10 Concert Pharmaceuticals Inc Compuestos de morfina.
CA2685924A1 (en) * 2007-05-01 2008-11-13 Concert Pharmaceuticals Inc. Naphthyl(ethyl)acetamides
DK2792662T3 (da) 2007-05-01 2016-07-25 Concert Pharmaceuticals Inc Morphinanforbindelser
PL2522667T3 (pl) * 2007-05-01 2015-01-30 Concert Pharmaceuticals Inc Związki morfinanu
AU2008256684B2 (en) * 2007-05-25 2012-06-14 Micell Technologies, Inc. Polymer films for medical device coating
WO2008156632A1 (en) 2007-06-12 2008-12-24 Concert Pharmaceuticals, Inc. Azapeptide derivatives
US8410124B2 (en) * 2007-10-18 2013-04-02 Concert Pharmaceuticals Inc. Deuterated etravirine
CA2716788C (en) 2008-02-29 2016-08-16 Concert Pharmaceuticals, Inc. Deuterium-substituted xanthine derivatives
SG192523A1 (en) 2008-04-17 2013-08-30 Micell Technologies Inc Stents having bioabsorbable layers
WO2009146310A1 (en) * 2008-05-28 2009-12-03 Concert Pharmaceuticals Inc. Deuterated tizanidine
JP2011528275A (ja) 2008-07-17 2011-11-17 ミセル テクノロジーズ，インク． 薬物送達医療デバイス
US9510856B2 (en) 2008-07-17 2016-12-06 Micell Technologies, Inc. Drug delivery medical device
WO2010019557A1 (en) * 2008-08-12 2010-02-18 Concert Pharmaceuticals Inc. N-phenyl-2-pyrimidineamine derivatives
ES2750825T3 (es) 2008-09-19 2020-03-27 Concert Pharmaceuticals Inc Compuestos de morfinano deuterados
PL2397158T3 (pl) 2008-10-30 2016-09-30 Skojarzone podawanie związków morfinanów oraz leków przeciwdepresyjnych w leczeniu nietrzymania afektu
US20120053169A1 (en) 2008-10-30 2012-03-01 Amanda Thomas Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurological diseases, intractable and chronic pain and brain injury
JP2012507524A (ja) 2008-11-04 2012-03-29 アンカー セラピューティクス，インコーポレイテッド Ｃｘｃｒ４受容体化合物
US20110313004A1 (en) 2008-12-04 2011-12-22 Concert Pharmaceuticals, Inc. Deuterated pyridinones
US8834913B2 (en) 2008-12-26 2014-09-16 Battelle Memorial Institute Medical implants and methods of making medical implants
CN102282457A (zh) * 2009-01-21 2011-12-14 拜康有限公司 确定西罗莫司稳定性的方法和制备其稳定形式的工艺
US20110053961A1 (en) 2009-02-27 2011-03-03 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
US8563554B2 (en) 2009-03-17 2013-10-22 Concert Pharmaceuticals, Inc. Deuterated pyrazinoisoquinoline compounds
CA2756386C (en) * 2009-03-23 2019-01-15 Micell Technologies, Inc. Drug delivery medical device
WO2010111238A2 (en) * 2009-03-23 2010-09-30 Micell Technologies, Inc. Improved biodegradable polymers
WO2010120552A2 (en) 2009-04-01 2010-10-21 Micell Technologies, Inc. Coated stents
WO2010121187A2 (en) 2009-04-17 2010-10-21 Micell Techologies, Inc. Stents having controlled elution
WO2010138889A1 (en) 2009-05-28 2010-12-02 Concert Pharmaceuticals, Inc. Peptides for the treatment of hcv infections
WO2011005520A1 (en) 2009-06-23 2011-01-13 Concert Pharmaceuticals, Inc. Deuterium-modified triazolo-pyridazine derivatives as gaba-a receptor modulators
WO2011005421A2 (en) 2009-07-10 2011-01-13 Boston Scientific Scimed, Inc. Use of nanocrystals for a drug delivery balloon
US10080821B2 (en) 2009-07-17 2018-09-25 Boston Scientific Scimed, Inc. Nucleation of drug delivery balloons to provide improved crystal size and density
US20110015154A1 (en) * 2009-07-20 2011-01-20 Kellermann Gottfried H Supporting acetylcholine function
US8278460B2 (en) 2009-10-15 2012-10-02 Concert Pharmaceuticals, Inc. Substituted benzimidazoles
US20110098265A1 (en) * 2009-10-28 2011-04-28 Neuroscience, Inc. Methods for reducing cravings and impulses associated with addictive and compulsive behaviors
WO2011060216A1 (en) 2009-11-12 2011-05-19 Concert Pharmaceuticals Inc. Substituted azaindoles
EP2531140B1 (en) 2010-02-02 2017-11-01 Micell Technologies, Inc. Stent and stent delivery system with improved deliverability
WO2011103457A1 (en) 2010-02-18 2011-08-25 Concert Pharmaceuticals Inc. Pyrimidine derivatives
US9155795B2 (en) 2010-02-26 2015-10-13 Anchor Therapeutics, Inc. CXCR4 receptor compounds
US8513434B2 (en) 2010-03-02 2013-08-20 Concert Pharmaceuticals Inc. Tetrahydronaphthalene derivatives
US8575361B2 (en) 2010-03-02 2013-11-05 Concert Pharmaceuticals Inc. Tetrahydronaphthalene derivatives
US8795762B2 (en) 2010-03-26 2014-08-05 Battelle Memorial Institute System and method for enhanced electrostatic deposition and surface coatings
EP2560576B1 (en) 2010-04-22 2018-07-18 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
US9101541B2 (en) 2010-04-28 2015-08-11 Cadila Healthcare Limited Stable solid pharmaceutical matrix compositions of sirolimus
IT1400977B1 (it) 2010-07-01 2013-07-05 Euticals Spa Nuovi complessi di inclusione farmaceutici, solidi, solubili in acqua e le loro soluzioni acquose per uso orale, oftalmico, topico o parenterale, contenenti un macrolide ed alcune ciclodestrine.
WO2012009684A2 (en) 2010-07-16 2012-01-19 Micell Technologies, Inc. Drug delivery medical device
WO2012031236A1 (en) 2010-09-02 2012-03-08 Boston Scientific Scimed, Inc. Coating process for drug delivery balloons using heat-induced rewrap memory
WO2012034079A2 (en) 2010-09-09 2012-03-15 Micell Technologies, Inc. Macrolide dosage forms
EP2616467A1 (en) 2010-09-13 2013-07-24 Concert Pharmaceuticals Inc. Substituted azaindoles
WO2012065028A2 (en) 2010-11-11 2012-05-18 Concert Pharmaceuticals Inc. Substituted tetracyclines
WO2012079075A1 (en) 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Deuterated phthalimide derivatives
US8447329B2 (en) 2011-02-08 2013-05-21 Longsand Limited Method for spatially-accurate location of a device using audio-visual information
WO2012116288A1 (en) 2011-02-25 2012-08-30 Concert Pharmaceuticals Inc. 2-amino-naphthyridine derivatives
WO2012129381A1 (en) 2011-03-22 2012-09-27 Concert Pharmaceuticals Inc. Deuterated preladenant
US20140213553A1 (en) 2011-05-03 2014-07-31 Concert Pharmaceuticals Inc. Carbamoylpyridone derivatives
WO2012154728A1 (en) 2011-05-10 2012-11-15 Concert Pharmaceuticals Inc. Deuterated n-butyl bumetanide
MX349159B (es) 2011-05-18 2017-07-14 Concert Pharmaceuticals Inc Derivados deuterados de ivacaftor.
WO2012166819A1 (en) 2011-05-31 2012-12-06 Micell Technologies, Inc. System and process for formation of a time-released, drug-eluting transferable coating
WO2013012689A1 (en) 2011-07-15 2013-01-24 Micell Technologies, Inc. Drug delivery medical device
WO2013013052A1 (en) 2011-07-19 2013-01-24 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
WO2013022458A1 (en) 2011-08-05 2013-02-14 Boston Scientific Scimed, Inc. Methods of converting amorphous drug substance into crystalline form
WO2013028208A1 (en) * 2011-08-25 2013-02-28 Boston Scientific Scimed, Inc. Medical device with crystalline drug coating
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
CN104254540A (zh) 2012-01-09 2014-12-31 安科治疗公司 Apj受体化合物
WO2013130849A1 (en) 2012-02-29 2013-09-06 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
WO2013155465A1 (en) 2012-04-13 2013-10-17 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
WO2013159026A1 (en) 2012-04-20 2013-10-24 Concert Pharmaceuticals, Inc. Deuterated rigosertib
AU2013274030B2 (en) 2012-06-15 2016-07-07 Sun Pharmaceutical Industries, Inc. Deuterated derivatives of ruxolitinib
ES2694202T3 (es) 2012-07-12 2018-12-19 Concert Pharmaceuticals, Inc. Idebenona deuterada
MX361499B (es) 2012-08-17 2018-12-06 Concert Pharmaceuticals Inc Baricitinib deuterado.
MY183582A (en) 2012-11-19 2021-02-26 Vertex Pharmaceuticals Europe Ltd Deuterated cftr potentiators
WO2014100431A1 (en) 2012-12-20 2014-06-26 Concert Pharmaceuticals, Inc. Deuterated alk inhibitors
EP3470070B1 (en) 2012-12-21 2021-04-28 Mayo Foundation for Medical Education and Research Methods and materials for treating calcific aortic valve stenosis
WO2014110322A2 (en) 2013-01-11 2014-07-17 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
EP2967803B1 (en) 2013-03-12 2023-12-27 Micell Technologies, Inc. Bioabsorbable biomedical implants
CA2904054A1 (en) 2013-03-15 2014-09-25 Concert Pharmaceuticals, Inc. Deuterated palbociclib
EP2968268B1 (en) 2013-03-15 2020-07-29 Concert Pharmaceuticals Inc. Inhibitors of the enzyme udp-glucose: n-acyl-sphingosine glucosyltransferase
HU231191B1 (hu) 2013-04-15 2021-08-30 Szegedi Tudományegyetem Izotóp tartalmú morfin molekulák
EP2996629B1 (en) 2013-05-15 2021-09-22 Micell Technologies, Inc. Bioabsorbable biomedical implants
WO2015009889A1 (en) 2013-07-18 2015-01-22 Concert Pharmaceuticals, Inc. Deuterated intedanib derivatives and their use for the treatment of proliferative disorders
WO2015010045A1 (en) 2013-07-18 2015-01-22 Anchor Therapeutics, Inc. Apj receptor compounds
US9676790B2 (en) 2013-08-30 2017-06-13 Concert Pharmaceuticals, Inc. Substituted thienotriazolodiazapines
DE102013110294B4 (de) 2013-09-18 2016-07-07 Innora Gmbh Limus-Depot-Formulierung auf Ballonkathetern
JP6529012B2 (ja) 2013-10-08 2019-06-12 エイアイ・セラピューティクス・インコーポレーテッド リンパ脈管筋腫症の処置のためのラパマイシン
US9694017B2 (en) 2014-02-10 2017-07-04 Concert Pharmaceuticals, Inc. Substituted triazolobenzodiazepines
AU2015217349A1 (en) 2014-02-11 2016-09-08 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
US10307371B2 (en) 2014-02-11 2019-06-04 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
US20170014341A1 (en) 2014-04-04 2017-01-19 Lam Therapeutics, Inc. An Inhalable Rapamycin Formulation for Treating Age-Related Conditions
CN106456647A (zh) 2014-04-18 2017-02-22 康塞特医药品有限公司 治疗高血糖症的方法
WO2015179772A1 (en) 2014-05-23 2015-11-26 Concert Pharmaceuticals, Inc. Deuterated phenylquinazolinone and phenylisoquinolinone compounds
CN106459004B (zh) 2014-06-06 2020-09-15 研究三角协会 爱帕琳肽受体(apj)激动剂及其用途
US10301273B2 (en) 2014-08-07 2019-05-28 Mayo Foundation For Medical Education And Research Compounds and methods for treating cancer
CN107249576A (zh) 2014-10-07 2017-10-13 拉姆医疗公司 用于治疗肺高压的可吸入雷帕霉素制剂
WO2016061488A1 (en) 2014-10-17 2016-04-21 Concert Pharmaceuticals, Inc. Amine reuptake inhibitors
WO2016073545A1 (en) 2014-11-06 2016-05-12 Concert Pharmaceuticals, Inc. Phenyloxadiazole benzoic acids
MA40910A (fr) 2014-11-07 2017-09-12 Civitas Therapeutics Inc Poudres de rapamycine pour administration pulmonaire
WO2016089814A1 (en) 2014-12-02 2016-06-09 Concert Pharmaceuticals, Inc. Deuterated analogues of daclatasvir
WO2016105547A1 (en) 2014-12-24 2016-06-30 Concert Pharmaceuticals, Inc. Deuterated dasabuvir
WO2016109795A1 (en) 2014-12-31 2016-07-07 Concert Pharmaceuticals, Inc. Deuterated funapide and difluorofunapide
WO2016130645A1 (en) 2015-02-10 2016-08-18 Lam Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
WO2016144830A1 (en) 2015-03-06 2016-09-15 Concert Pharmaceuticals, Inc. Deuterated emricasan
US10196384B2 (en) 2015-03-31 2019-02-05 Vertex Pharmaceuticals (Europe) Limited Deuterated CFTR modulators
WO2016176335A1 (en) 2015-04-27 2016-11-03 Concert Pharmaceuticals, Inc. Deuterated otx-015
WO2017020002A1 (en) 2015-07-30 2017-02-02 Concert Pharmaceuticals, Inc. Deuterated morphinan compounds for use in treating agitation
WO2017020005A1 (en) 2015-07-30 2017-02-02 Concert Pharmaceuticals, Inc. Morphinan compounds for use in treating agitation
EP4292588A3 (en) 2015-09-21 2024-02-28 Vertex Pharmaceuticals (Europe) Limited Administration of deuterated cftr potentiators
WO2017087795A1 (en) 2015-11-19 2017-05-26 Concert Pharmaceuticals, Inc. Deuterated epi-743
AU2016366310C1 (en) 2015-12-09 2021-09-09 Research Triangle Institute Improved apelin receptor (APJ) agonists and uses thereof
WO2017147003A1 (en) 2016-02-26 2017-08-31 Novobiotic Pharmaceuticals, Llc Novel macrocyclic antibiotics and uses thereof
FI3452039T3 (fi) 2016-05-04 2024-10-02 Sun Pharmaceutical Ind Inc Hiustenlähtöhäiriöiden hoito deuteroiduilla JAK-estäjillä
ES2925277T3 (es) 2016-07-04 2022-10-14 Avanir Pharmaceuticals Inc Métodos para la síntesis de dextrometorfano deuterado
WO2018026833A1 (en) 2016-08-01 2018-02-08 The Brigham And Women's Hospital, Inc. Particles for delivery of proteins and peptides
US11285116B2 (en) * 2016-08-19 2022-03-29 Aron H. Blaesi Method for the manufacture of fibrous dosage forms
AU2017382217B2 (en) 2016-12-21 2021-07-08 Research Triangle Institute Diaryl purine derivatives with improved bioavailability
EP3589659A4 (en) 2017-02-28 2021-03-24 Mayo Foundation for Medical Education and Research CANCER TREATMENT COMPOUNDS AND METHODS
US11278025B2 (en) 2017-05-17 2022-03-22 The General Hospital Corporation Antibiotic compounds
MX2019013769A (es) 2017-05-19 2020-07-20 Superb Wisdom Ltd Derivados de resiquimod.
MX2020005336A (es) 2017-11-22 2020-08-13 Concert Pharmaceuticals Inc Analogos de d-serina deuterados y usos de los mismos.
WO2019183109A1 (en) * 2018-03-19 2019-09-26 Gemini Laboratories, Llc Immunosuppressive dosage forms and methods of use
US11243207B2 (en) 2018-03-29 2022-02-08 Mayo Foundation For Medical Education And Research Assessing and treating cancer
JP7492723B2 (ja) * 2019-12-02 2024-05-30 ノーベルファーマ株式会社 シロリムス含有顆粒製剤、及びその製造方法
CA3165259A1 (en) * 2019-12-19 2021-06-24 Triviumvet Dac Veterinary formulations comprising rapamycin and methods of using the same for treating animal diseases
WO2021236139A1 (en) 2020-05-21 2021-11-25 Concert Pharmaceuticals, Inc. Novel deuterated jak inhibitor and uses thereof
KR20230093504A (ko) 2020-10-28 2023-06-27 썬 파마슈티칼 인더스트리즈 인코포레이티드 중수소화된 jak 억제제를 이용한 탈모 장애의 치료를 위한 요법
CN118159272A (zh) 2021-08-11 2024-06-07 太阳医药工业公司 用氘化的jak抑制剂来治疗脱发病症
CA3228509A1 (en) 2021-08-12 2023-02-16 Sun Pharmaceutical Industries, Inc. Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors
WO2023215520A1 (en) 2022-05-04 2023-11-09 Sun Pharmaceutical Industries, Inc. Dosage regimens for treatment with deuterated jak inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
FR2736550B1 (fr) * 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
KR100505464B1 (ko) * 1998-03-26 2005-08-04 후지사와 야꾸힝 고교 가부시키가이샤 서방성 제제
GB9826882D0 (en) * 1998-12-07 1999-01-27 Novartis Ag Organic compounds
CA2536775A1 (en) * 2003-09-03 2005-03-17 Wyeth Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions containing the same

Also Published As

Publication number Publication date
WO2006039237A1 (en) 2006-04-13
AU2005292339A1 (en) 2006-04-13
CA2581169A1 (en) 2006-04-13
MX2007003731A (es) 2007-08-14
IL182255A0 (en) 2007-09-20
KR20070083839A (ko) 2007-08-24
JP2008514706A (ja) 2008-05-08
EP1809247A1 (en) 2007-07-25
US20060094744A1 (en) 2006-05-04
CN101076319A (zh) 2007-11-21

Similar Documents

Publication Publication Date Title
BRPI0516170A (pt) formas de dosagens farmacêuticas estáveis e amorfas de compostos de rapamicina
IL212586A (en) Derivative 3 - (1, 3-benzoxazole-5-yl) pyrzolo [3, 4-d] pyrimidine-4-amine, a pharmaceutical preparation and the use of a drug derivative
DK1928503T3 (da) Fremgangsmåde til fremstilling af oprensede lægemiddelkonjugater
NO20084526L (no) Tienpyrimidiner med MNKL/MNK2 inhiberende aktivitet for farmasøytiske sammensetninger
ATE532788T1 (de) Pharmazeutische verbindungen
CU20080052A7 (es) Formas de presentación farmacéutica sólidas de administración oral con liberación rápida de principio activo
CR11568A (es) Compuestos de 3h-[1,2,3]triazolo[4,5-d]pirimidina, su uso como inhibidores de mtor quinasa y pi3 quinasa y su sintesis
LT2046298T (lt) Farmacinė vaisto forma, turinti farmaciniu požiūriu priimtiną soliubilizuojančią kompoziciją
ECSP12011961A (es) 2-amino-5,5-difluor-5,6-dihidro-4h-oxazinas como inhibidores de
UY27138A1 (es) Composiciones farmacéuticas, formas de dosificación y métodos para la administración oral de epotilonas.
ECSP11011054A (es) Péptidos antivirales terapéuticos
LU92326I2 (fr) Canakinumab et ses dérivés pharmaceutiquement acceptables (ILARIS)
ECSP066883A (es) Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes
ECSP12012339A (es) Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida monohidratado
BRPI0606322A2 (pt) formulações intravenosas de inibidores de pde-5
CO6640318A2 (es) Formas de dosificación oral de bendamustina
DOP2006000024A (es) Tiazolidinonas, su preparación y su uso como medicamento
BR122016006880B8 (pt) forma de dosagem contendo pantoprazol como ingrediente ativo
BRPI0821454A2 (pt) Formulação farmacêutica, excipiente para a preparação de formulação farmacêuticas de liberação lenta, e, processos para a produção de um excipiente de liberação lenta, e de uma forma farmacêutica.
RS52430B (en) SUBLINGVAL FORMULATION OF DIHIDROARTEMEZININE CONTAINING SPRAY
UY30550A1 (es) Nuevos beta-agonistas enantioméricamente puros, procedimientos para su preparacion y su uso como medicamentos
CR9211A (es) Composiciones que comprenden una epotilona y metodos de produccion
AR060348A1 (es) Formas polimorficas de (2r,z)-2-amino-2-ciclohexil-n-(5-(1-metil-1h-pirazol-4-il)-1-oxo-2,6-dihidro-1h-(1,2)diazepino(4,5,6-cd)indol-8-il)acetamida (2r,z)-2--amino-2-ciclohexil-n-(5-(1-metil-1h-pirazol-4-il)-1-oxo-2,6-dihidro-1h-[1,2]diazepino[4,5,6-cd]indol-8-il)acetamida (2r,z)-2--amino-2-ciclohex
DK1853296T3 (da) Anvendelse af et cyklisk undekapeptid til fremstilling af et lægemiddel indgift ved myokardiale iskæmiepisoder
ITTO20060264A1 (it) Procedimento di fabbricazione di una struttura di memoria non volatile mediante litografia "soffice"

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.